The U.S. Supreme Court on Thursday rejected a lawsuit challenging the Food and Drug Administration’s (FDA) approach to regulating the abortion pill mifepristone, allowing the drug to continue to be provided by mail without an in-person doctor’s visit. In a unanimous...
